Recently, PKM2 has been reported to promote PD-L1 (programmed cell death 1 ligand 1) expression in tumor, and PKM2 activators might synergize with PD-1 (programmed cell death 1)/PD-L1 checkpoint inhibitors to provide suppressive roles to tumor immune escape [166]. Here, PKM is linked to neoplasm.